Linking Intermediate to Final “Real-World” Outcomes: Is Financial Toxicity a Reliable Predictor of Poorer Outcomes in Cancer?

Traditionally, economic evaluations are based on clinical trials with well-defined patient populations that exclude many patient types. By contrast, studies that incorporate general patient populations end up including those in lower income categories, some of whom have significant financial burdens...

Descripción completa

Detalles Bibliográficos
Autor principal: Longo, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027087/
https://www.ncbi.nlm.nih.gov/pubmed/35448176
http://dx.doi.org/10.3390/curroncol29040202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027087/
https://www.ncbi.nlm.nih.gov/pubmed/35448176
http://dx.doi.org/10.3390/curroncol29040202

Ejemplares similares